- Home
- ERNA
as 07-05-2024 4:00pm EST
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 10.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 5.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $2.99 | Next Earning Date: | 08-09-2024 |
| Revenue: | $115,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Eterna Therapeutics Inc. News
ERNA Breaking Stock News: Dive into ERNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
GlobeNewswire
2 months ago
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
GlobeNewswire
2 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
GlobeNewswire
2 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
GlobeNewswire
5 months ago
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
ACCESSWIRE
5 months ago
Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of January 31, 2024, for TYG, NTG, TTP, NDP and TPZ
GlobeNewswire
5 months ago
Lofty Unveils AI Powered Virtual Assistant at Inman Connect New York
PR Newswire
6 months ago
Future FinTech Responds to Inquiry of CEO
Share on Social Networks:
Disclaimer
The information presented on this page, "ERNA Eterna Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.